NEW YORK, April 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI).Shareholders who purchased shares of TMCI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/treace-medical-concepts-inc-loss-submission-form-2/?id=143353&from=4CLASS ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Treace Medical Concepts, Inc. securities for the period between May 8, 2023, and May 7, 2024, due to alleged misleading statements and failure to disclose critical information regarding the company's primary product and its market performance [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Treace Medical's management made false and/or misleading statements about the demand for its Lapiplasty 3D Bunion Correction System, which led to a decline in revenue and necessitated an accelerated product development plan [5]. - The lawsuit alleges that the positive statements made by Treace Medical regarding its business operations and prospects were materially misleading and lacked a reasonable basis [5]. Group 2: Participation Information - Investors who purchased Treace Medical securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Treace Medical Concepts, Inc. (“Treace Medical” or “the Company”) (NASDAQ: TMCI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise a ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Treace Medical To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Treace Medical between May 8, 2023, and May 7, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 16, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Treace Medical Concepts, Inc. ("Treace Medical" or the "Company") (NASDAQ: TMCI) investors of a class action representing investors that bought securities between May 8, 2023 and May 7, 2024, inclusive (the "Class Period"). Treace Medical investors have until June 10, 2025 to file a lead plaintiff motion. Investors are encouraged to contact at ...

Core Points - A class action has been filed against Treace Medical Concepts, Inc. for allegedly misleading investors regarding the demand for its primary product, the Lapiplasty 3D Bunion Correction System [1][2] - The complaint states that competition negatively impacted the demand and utilization of the Lapiplasty system, leading to a decline in Treace Medical's revenue [2] - Following the revelation of these issues, Treace Medical's stock price dropped nearly 63%, closing at $4.17 per share on May 8, 2024 [2] Company Overview - Treace Medical Concepts, Inc. focuses on advancing surgical management standards for bunion and related midfoot deformities [1] - The company is under scrutiny for its failure to disclose critical information regarding competition and product demand [2] Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file their papers by June 10, 2025 [3] - Participation in the class action is not mandatory for recovery; shareholders can remain absent class members [3] Firm Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - A class action lawsuit has been filed against Treace Medical Concepts, Inc. for alleged misleading statements and failure to disclose critical information regarding its primary product, the Lapiplasty 3D Bunion Correction System, impacting investor decisions during the specified Class Period [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Treace Medical securities between May 8, 2023, and May 7, 2024 [1]. - Allegations include that competition affected the demand for the Lapiplasty system, leading to a decline in revenue and necessitating an accelerated product development plan [5]. - The lawsuit claims that the defendants made materially misleading statements about the company's business and prospects, resulting in investor damages when the truth was revealed [5]. Group 2: Participation Information - Investors who purchased Treace Medical securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by June 10, 2025, to represent other class members [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in previous years, including over $438 million in 2019 [4].

Core Viewpoint - A securities class action lawsuit has been filed against Treace Medical Concepts, Inc. for allegedly making false and misleading statements regarding its business operations and financial performance during the specified class period [1][2]. Company Summary - The lawsuit claims that Treace Medical failed to disclose significant competition affecting the demand for its primary product, the Lapiplasty 3D Bunion Correction System, leading to a decline in revenue [2]. - The company is accused of needing to accelerate plans to introduce an alternative product to osteotomy due to competitive pressures [2]. - Positive statements made by the company regarding its business prospects are alleged to be materially misleading [2]. Financial Impact - On May 7, 2024, Treace Medical reported its financial results, revealing that competition from minimally invasive osteotomy and Lapiplasty knockoffs hindered growth [3]. - Following this announcement, the company's stock price plummeted by $6.95, nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [4].

Core Viewpoint - A securities class action lawsuit has been filed against Treace Medical Concepts, Inc. for allegedly misleading statements regarding its business and financial condition, leading to significant stock price declines during the class period [1][4][5]. Group 1: Lawsuit Details - The lawsuit was filed by Scott+Scott Attorneys at Law LLP in the U.S. District Court for the Middle District of Florida against Treace Medical and certain officers/directors [1]. - The class action asserts claims under the Securities Exchange Act of 1934 and SEC Rule 10b-5 for individuals who purchased Treace Medical securities between May 8, 2023, and May 7, 2024 [1]. - The lead plaintiff deadline for the lawsuit is June 10, 2025 [2][6]. Group 2: Company Overview - Treace Medical is a medical technology company focused on surgical management of bunion and related midfoot deformities, with its primary product being the patented Lapiplasty system [3]. Group 3: Allegations Against Defendants - The lawsuit alleges that during the class period, defendants made misleading statements about the company's business and financial prospects, failing to disclose competition affecting demand for the Lapiplasty system [4]. - It is claimed that Treace Medical's revenue declined, necessitating an acceleration of plans to offer alternative products to osteotomy [4]. - Defendants' positive statements about the company's operations were allegedly materially misleading and lacked a reasonable basis [4]. Group 4: Impact on Stock Price - Following the revelation of the company's lowered revenue guidance from $220 million-$225 million to $201 million-$211 million on May 7, 2024, Treace Medical's stock price fell by $6.95, or nearly 63%, closing at $4.17 per share on May 8, 2024 [5].

Core Insights - Treace Medical Concepts, Inc. presented updated interim data for its clinical studies on Lapiplasty and Adductoplasty procedures at the 2025 ACFAS Annual Meeting, highlighting positive clinical outcomes and the differentiation of these procedures in the market [1][2]. Clinical Study Summaries - **ALIGN3D™ Lapiplasty Clinical Study**: The interim analysis included 135 of 173 patients with at least four years of follow-up, showing low radiographic recurrence rates of 0.8% using HVA>20° and 7.7% using HVA>15° at 48 months, along with significant improvements in pain and patient-reported outcomes [3][6]. - **Mini3D™ Lapiplasty Mini-Incision™ Clinical Study**: The study involved 75 of 105 patients with at least one year of follow-up, reporting early return to protected weightbearing at an average of 7.9 days and low recurrence rates of 0.0% using HVA>20° and 5.5% using HVA>15° at 12 months [4][7]. - **MTA3D™ Adductoplasty Clinical Study**: This study included 18 of 38 patients with at least one year of follow-up, showing early return to protected weightbearing at an average of 7.5 days and clinically significant improvements in pain and patient-reported scores at 12 months [5][8]. Company Overview - Treace Medical Concepts is focused on advancing surgical management for bunions and related midfoot deformities, with an estimated 1.1 million annual surgical candidates in the U.S. [15][16]. The company has developed the Lapiplasty 3D Bunion Correction System and the Adductoplasty Midfoot Correction System to address these conditions [15][16].